Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sézary syndrome

Despite recent therapeutic improvements, the prognosis for patients suffering from Sézary syndrome (SS), a disseminated form of cutaneous T-cell lymphomas, is still poor. We identified bi- and monoallelic deletions of the tumor necrosis factor-α-induced protein 3 gene (TNFAIP3; A20) in a high proportion of SS patients as well as biallelic A20 deletion in the SS-derived cell line SeAx. Furthermore, we demonstrate that inhibition of A20 activates the NF-κB pathway thereby increasing the proliferation of normal T lymphocytes. On the other hand, the reconstitution of A20 expression slowed down the cell cycle in SeAx cells. Recently A20 inactivation has been reported in various B-cell lymphomas. In this study, we show that A20 is also a putative tumor suppressor in the T-cell malignancy—SS.

[1]  Nicola Pimpinelli,et al.  WHO-EORTC classification for cutaneous lymphomas. , 2005, Blood.

[2]  Rudi Beyaert,et al.  A20 inhibits NF-κB activation by dual ubiquitin-editing functions , 2005 .

[3]  Somasekar Seshagiri,et al.  De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling , 2004, Nature.

[4]  Bettina L. Lee,et al.  Homeostatic MyD88-dependent signals cause lethal inflamMation in the absence of A20 , 2008, The Journal of experimental medicine.

[5]  K. Thomsen,et al.  A continuous T-cell line from a patient with Sézary syndrome , 2004, Archives of Dermatological Research.

[6]  A. Gazdar,et al.  Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor , 1981, The Journal of experimental medicine.

[7]  P. Marynen,et al.  A20 Negatively Regulates T Cell Receptor Signaling to NF-κB by Cleaving Malt1 Ubiquitin Chains1 , 2009, The Journal of Immunology.

[8]  A. Leonardi,et al.  A20 is a negative regulator of BCL10- and CARMA3-mediated activation of NF-κB , 2008, Journal of Cell Science.

[9]  A. Krikos,et al.  Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements. , 1992, The Journal of biological chemistry.

[10]  R. Contreras,et al.  The zinc finger protein A20 interacts with a novel anti-apoptotic protein which is cleaved by specific caspases , 1999, Oncogene.

[11]  J. Boer,et al.  Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. , 2009, Blood.

[12]  P. Fadda,et al.  Identification of key regions and genes important in the pathogenesis of sezary syndrome by combining genomic and expression microarrays. , 2009, Cancer research.

[13]  Y. Lo,et al.  Molecular Basis for the Unique Deubiquitinating Activity of the NF-κ B Inhibitor A 20 , 2008 .

[14]  G Cantarella,et al.  Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation. , 2000, Immunity.

[15]  H. Tagawa,et al.  TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. , 2009, Blood.

[16]  R. Beyaert,et al.  A20 inhibits NF-kappaB activation by dual ubiquitin-editing functions. , 2005, Trends in biochemical sciences.

[17]  S. Ogawa,et al.  Frequent inactivation of A20 in B-cell lymphomas , 2009, Nature.

[18]  G. Courtois,et al.  Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. , 2006, Blood.

[19]  P. Marynen,et al.  T cell antigen receptor stimulation induces MALT1 paracaspase–mediated cleavage of the NF-κB inhibitor A20 , 2008, Nature Immunology.

[20]  Zhijian J. Chen,et al.  The role of ubiquitin in NF-kappaB regulatory pathways. , 2009, Annual review of biochemistry.

[21]  L. Pasqualucci,et al.  The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. , 2008, Blood.

[22]  F. W. Wolf,et al.  Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. , 1990, The Journal of biological chemistry.

[23]  W. Fiers,et al.  Inhibition of tumor necrosis factor-induced necrotic cell death by the zinc finger protein A20. , 1999, Anticancer research.

[24]  A. Ma,et al.  Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. , 2000, Science.

[25]  H. Müller-Hermelink,et al.  A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation‐negative MALT lymphoma of the ocular adnexa and salivary glands , 2009, The Journal of pathology.

[26]  W. Klapper,et al.  TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma , 2009, The Journal of experimental medicine.

[27]  E. Boel,et al.  Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides , 1992, In Vitro Cellular & Developmental Biology - Animal.